Gene therapy joins forces with chemo and immunotherapy to fight bladder cancer
NCT ID NCT07332351
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This phase 2 trial tests whether adding a gene therapy called nadofaragene firadenovec to standard chemotherapy and immunotherapy can improve outcomes for people with muscle invasive bladder cancer before they have their bladder removed. The gene therapy is placed directly into the bladder and helps it produce a natural protein that fights cancer. About 33 participants will receive the combination, and researchers will check if the cancer disappears completely after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA BLADDER CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nadofaragene firadenovec (gene therapy), durvalumab (immunotherapy), gemcitabine and cisplatin (chemotherapy)
What this could lead to
If successful, this combination could improve the chance of eliminating all cancer before bladder removal surgery, potentially reducing recurrence and improving survival.
What could go wrong
This is an early phase 2 trial with only 33 participants, so results may not apply broadly. Adding gene therapy to standard treatment could increase side effects, and the study is not yet recruiting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.